Table 1.
Details of the study patients
| Sr. no | Age/sex | Primary diagnosis | Site | Initial treatment | Metastatic sites | First-line CT (no. of cycles) | Second-line CT (no. of cycles) | Palliative RT (local site) | Disease status at 3 mo of metronomic CT | Disease status at 6 mo of metronomic CT |
|---|---|---|---|---|---|---|---|---|---|---|
| 1) | 35/ F | Angiosarcoma | Right breast | Surgery | Bone marrow | I + A (6) | T (5) | 20 Gy, 5# | PR | SD |
| 2) | 47/ M | Angiosarcoma | Left lung | Surgery | Liver | I + A (6) | G (6) | 30 Gy, 10# | PR | SD |
| 3) | 42/ F | Angiosarcoma | Left breast | Surgery | Lung | I + A (6) | G (6) | 30 Gy, 10# | SD | SD |
| 4) | 32/ F | IMT | Retro peritoneum | Surgery | Liver | P + A (6) | I (5) | 30 Gy, 10# | PR | SD |
| 5) | 55/ M | Fibro sarcoma | Right lung | Surgery | Bone | MAID (6) | V (6) | 30 Gy, 10# | SD | SD |
| 6) | 51/ M | Fibro sarcoma | Left lung | Surgery | Brain | WBRT, I + A (6) | G (6) | 30 Gy, 10# | SD | SD |
| 7) | 38/ F | MFH | Right breast | Surgery | Brain | WBRT, I + A (6) | G (5) | 20 Gy, 5# | SD | SD |
| 8) | 31/ M | MFH | Left kidney | Surgery | Liver | I + A (6) | T (6) | 20 Gy, 5# | PR | SD |
| 9) | 15/ M | MFH | Right maxillary sinus | Surgery | Brain | WBRT, D (6) | Pazopanib (6 mo) | 20 Gy, 5# | SD | SD |
| 10) | 47/ M | MFH | Right lung | Surgery | Lung | I + A (6) | T (6) | 20 Gy, 5# | SD | SD |
| 11) | 28/ F | MPT | Right breast | Surgery | Liver | I (6) | D (6) | 30 Gy, 10# | SD | SD |
| 12) | 38/ F | MPT | Right breast | Surgery | Liver | I + A (6) | G (5) | 30 Gy, 10# | SD | SD |
| 13) | 42/ F | MPT | Left breast | Surgery | Lung | I(6) | D (6) | 30 Gy, 10# | PR | SD |
| 14) | 61/ F | LMS | Uterus | Surgery | Liver | D + G (6) | I (6) | 30 Gy, 10# | PR | SD |
| 15) | 42/ M | DFSP | Anterior abdominal wall | Surgery | Lung, liver | Imatinib (8 mo) | Sorafenib (5 mo) | 20 Gy, 5# | PR | SD |
| 16) | 45/ M | Synovial | Right | Surgery | Liver, brain | WBRT, D | I (6) | 20 Gy, 5# | SD | SD |
MFH, malignant fibrohistiocytic sarcoma; DFSP, dermatofibrosarcoma protuberance; CT, chemotherapy; RT, radiotherapy; M, male; F, female; DFS, disease-free survival; MAID, mesna, doxorubicin, ifosfamide, dacarbazine; WBRT, whole brain radiotherapy; SA, single agent; IMT, inflammatory myofiroblastic tumor; + A, adriamycin + ifosfamide; P + A, cisplatin + adriamycin; G, gemcitabine; D, doxorubicin; I, ifosfamide; D + G, docetaxel + gemcitabine; G, gemcitabine; T, paclitaxel; V, vinorelbine; mo, months; SD, stable disease; PR, partial response; PD, progressive disease; LMS, leiomyosarcoma; MPT, malignant phylloides tumor